Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer.

Andre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, Delaloge S, Tomasic G, Spielmann M, Esteva FJ, Rimm DL, Michiels S.

Ann Oncol. 2012 Aug;23(8):2059-64. doi: 10.1093/annonc/mdr569. Epub 2012 Jan 11.

PMID:
22241898
2.

Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.

Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL.

J Clin Oncol. 2011 Aug 1;29(22):2978-84. doi: 10.1200/JCO.2010.32.9706. Epub 2011 Jun 27.

3.

Quantitative, fluorescence-based in-situ assessment of protein expression.

Moeder CB, Giltnane JM, Moulis SP, Rimm DL.

Methods Mol Biol. 2009;520:163-75. doi: 10.1007/978-1-60327-811-9_12.

PMID:
19381954
4.

Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.

Giltnane JM, Moeder CB, Camp RL, Rimm DL.

Cancer. 2009 Jun 1;115(11):2400-9. doi: 10.1002/cncr.24277.

5.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL.

Mod Pathol. 2008 Sep;21(9):1121-9. doi: 10.1038/modpathol.2008.100. Epub 2008 Jun 13.

6.

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2008;10(2):R35. doi: 10.1186/bcr1998. Epub 2008 Apr 23.

7.

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Dec 1;25(34):5418-25.

PMID:
18048824
8.

Bimodal population or pathologist artifact?

Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B.

J Clin Oncol. 2007 Jun 10;25(17):2487-8. No abstract available.

PMID:
17557963
9.

High HSP90 expression is associated with decreased survival in breast cancer.

Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM.

Cancer Res. 2007 Apr 1;67(7):2932-7.

10.

Determination of bis(tributyltin) oxide by GC--MS with on-line hydride derivatization: application to drug substance analysis.

O'Brien TP, Dowling TM, Moeder CW, Bicker GR.

J Pharm Biomed Anal. 1999 Mar;19(3-4):327-33.

PMID:
10704098
11.

Mechanisms of retention of pyrrolidinyl norephedrine on immobilized alpha(1)-acid glycoprotein.

Yehl PM, O'Brien TP, Moeder CW, Grinberg N, Bicker G, Wyvratt J.

Chirality. 2000 Mar;12(3):107-13.

PMID:
10689288
12.

Mechanistic aspects of chiral discrimination on modified cellulose.

O'Brien T, Crocker L, Thompson R, Thompson K, Toma PH, Conlon DA, Feibush B, Moeder C, Bicker G, Grinberg N.

Anal Chem. 1997 Jun 1;69(11):1999-2007. doi: 10.1021/ac961241l.

PMID:
21639239
13.

Drug substance manufacture process control: application of flow injection analysis and HPLC for monitoring an enantiospecific synthesis.

Chong K, Loughlin T, Moeder C, Perpall HJ, Thompson R, Grinberg N, Smith GB, Bhupathy M, Bicker G.

J Pharm Biomed Anal. 1996 Oct;15(1):111-21.

PMID:
8895082

Supplemental Content

Loading ...
Support Center